Menu
Recruiting NCT04425265

Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma

No phase Interventional Surgery Recurrent Nasopharyngeal Carcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Plasma radiofrequency ablation, Electrocautery block resection.
Who it may be relevant to
Registry conditions: Surgery, Recurrent Nasopharyngeal Carcinoma. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Randomized Controlled Trial of Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma.

Overview

This study aims at exploring whether plasma radiofrequency ablation at low temperature is associated with better survival outcome in localized recurrent nasopharyngeal carcinoma by conducting a randomized controlled trial of plasma radiofrequency ablation at low temperature versus electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma. If the hypothesis is confirmed, it is expected to provide a convenient choice for the surgical treatment of localized recurrent nasopharyngeal carcinoma.

Interventions

  • Procedure Plasma radiofrequency ablation
    Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.
  • Procedure Electrocautery block resection
    Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the so

Primary outcome measures

  • Progression-free survival [Time frame: 2 years]
Secondary outcome measures (6)
  • Overall survival [Time frame: 2 years]
  • Loco-regional relapse-free survival [Time frame: 2 years]
  • Distant metastasis-free survival [Time frame: 2 years]
  • Incidence of surgery related complications [Time frame: 1 year]
  • Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) [Time frame: 1 year]
  • Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35) [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • At least 6 months disease free interval (defined as duration between the initial course of radiotherapy and recurrence)
  • Histopathologically diagnosed with undifferentiated or differentiated, nonkeratinizing nasopharyngeal carcinoma.
  • Resectable recurrent nasopharyngeal carcinoma: rT1-3N0-3M0 A) The tumor is confined to the nasopharyngeal mucosa, or the surface of the parapharyngeal space, or the bottom wall of the sphenoid sinus, and is more than 0.5cm away from the internal carotid artery B) The cervical lymph node lesions do not infiltrate the cervical spine, brachial plexus, cervical muscles, and internal carotid artery.
  • Age: 18-70 years old.
  • Subjects must sign an informed consent form.

Exclusion criteria

  • Karnofsky score (KPS)≤70.
  • Has known Subjects with other malignant tumors.
  • Has seriously mental disease.
  • Uncontrolled clinically significant heart disease and Pulmonary dysfunction.
  • Pregnancy or breast feeding.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 3 centers
  • Sun Yat-sen University Cancer Center — Guangzhou
  • The Fifth Affiliated Hospital of Sun Yat-sen University — Zhuhai
  • The Nanchang Affiliated Hospital, Sun Yat-Sen University (Nanchang First Hospital) — Nanchang

Identifiers

NCT: NCT04425265 · SYSUCC-CMY-2020-2301

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗